Multidrug resistance modulation studies in acute myeloid leukemia (AML).
| Group . | Modulator . | Regimen . | Outcome . |
|---|---|---|---|
| *De novo > 60 years | |||
| Abbreviations: SWOG, Southwest Oncology Group; MRC, Medical Research Council; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; CSP, cyclosporine; HiDAC, high-dose cytarabine; OS, Overall Survival; ADE, cytarabine, daunorubicin, etoposide; ME, mitoxantrone and etoposide; MEC, mitoxantrone, etoposide, cytarabine; DA, daunorubicin, cytarabine; RFS, relapse-free survival; OS, overall survival | |||
| SWOG | CSP | D/HiDAC ± CSP | RFS/OS improved |
| MRC | CSP | ADE ± CSP | No benefit |
| HOVON | CSP | ME ± CSP | No benefit |
| CALGB* | PSC-833 | ADE ± PSC-833 | No benefit |
| ECOG | PSC-833 | MEC ± PSC-833 | No benefit |
| HOVON* | PSC-833 | DA ± PSC-833 | No benefit |
| Group . | Modulator . | Regimen . | Outcome . |
|---|---|---|---|
| *De novo > 60 years | |||
| Abbreviations: SWOG, Southwest Oncology Group; MRC, Medical Research Council; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; CSP, cyclosporine; HiDAC, high-dose cytarabine; OS, Overall Survival; ADE, cytarabine, daunorubicin, etoposide; ME, mitoxantrone and etoposide; MEC, mitoxantrone, etoposide, cytarabine; DA, daunorubicin, cytarabine; RFS, relapse-free survival; OS, overall survival | |||
| SWOG | CSP | D/HiDAC ± CSP | RFS/OS improved |
| MRC | CSP | ADE ± CSP | No benefit |
| HOVON | CSP | ME ± CSP | No benefit |
| CALGB* | PSC-833 | ADE ± PSC-833 | No benefit |
| ECOG | PSC-833 | MEC ± PSC-833 | No benefit |
| HOVON* | PSC-833 | DA ± PSC-833 | No benefit |